雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Infrastructure for New Drug Development to Treat Muscular Dystrophy: Current Status of Patient Registration (Remudy) Harumasa Nakamura 1 , En Kimura 2 , Mitsuru Kawai 3 1Department of Neurology,National Center Hospital of Neurology and Psychiatry 2Translational Medical Center,National Center of Neurology and Psychiatry 3Department of Neurology,National Hospital Organization,Higashi-Saitama National Hospital Keyword: dystrophinopathy , databese , Remudy , TREAT-NMD , orphan drug pp.1279-1284
Published Date 2011/11/1
DOI https://doi.org/10.11477/mf.1416101063
  • Abstract
  • Look Inside
  • Reference

Abstract

 Clinical trials for new therapeutic strategies are now being planned for Duchenne and Becker muscular dystrophies (DMD/BMD); however, many challenges exist in the planning and conduction of a clinical trial for rare diseases. The epidemiological data, total number of patients, natural history, and clinical outcome measures are unclear. Adequate numbers of patients are needed to achieve significant results in clinical trials. As solutions to these problems, patient registries are an important infrastructure worldwide, especially in the case of rare diseases such as DMD/BMD. In Europe, TREAT-NMD, a clinical research network for neuromuscular disorders, developeda global database for dystrophinopathy patients. We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD. The database includes clinical and molecular genetic data as well as all required items for the TREAT-NMD global patient registry. As of July 2011, 750 patients were registered in the database. The purpose of this registry is the effective recruitment of eligible patients for clinical trials, and it may also provide timely information to individual patients about upcoming trials. This registry data also provides more detailed knowledge about natural history, epidemiology, and clinical care.

 In recent years,drug development has become dramatically globalized,and global clinical trials (GCTs) are being conducted in Japan. It is appropriate,particularly with regard to orphan diseases,to include Japanese patients in GCTs to increase evidence for evaluation,because such large-scale trials would be difficult to conduct solely within Japan. GCTs enable the synchronization of clinical drug development in Japan with that in Western countries,minimizing drug approval delays.


Copyright © 2011, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有